• On sale!


  • Montefarmaco OTC S.p.A.
  • 026630020
Iridina Due is a drug based on the active ingredient naphazoline hydrochloride (FU), belonging to the category of Decongestants and specifically Sympathomimetics used as decongestants. Iridina Due can be prescribed with OTC Recipe - self-medication. Irritation, burning, redness of the eye, with excessive tearing, and sensitivity to light.
info_outline View product sheet
Final Price €9.50

Volume discounts

Quantity Unit discount You Save
2 10% €1.90
5 20% €9.50
10 35% €33.25
check_circle Available
Shipped within 24 h
  Convenient and safe payments

Even with a credit card

  Shipping in 24h all over the world

Fast and safe international shipping worldwide

  Fast returns

14 days to reconsider

  Pharmaceutical experience

Always at your service. Experts in international shipping

Other products Others products at unbeatable price

Montefarmaco OTC S.p.A.

Discover all products


Therapeutic indications

Irritation, burning, redness of the eye, with excessive tearing, and sensitivity to light.

Dosage and method of use

When you feel the burning sensation, squeeze one or two drops of eye drops into the inner corner of each eye, tilting your head back. The product should not be used after 28 days from first opening. Strictly adhere to the recommended doses. A higher dosage of the product, even if taken topically and for a short period of time, can give rise to serious systemic effects.


Hypersensitivity to components or other closely related substances from a chemical point of view; in particular towards xylometazoline, oximetazoline, tetrizoline. The product should not be used in patients with glaucoma or other eye diseases. Contraindicated in children under the age of twelve. Concurrent treatment with monoamine oxidase inhibitors (see section 4.5).

Side effects

The use of the product can sometimes cause pupillary dilation, systemic absorption effects (hypertension, heart disease, hyperglycemia), increased intraocular pressure, nausea, headache. Hypersensitivity phenomena may rarely occur. In this case, the treatment must be interrupted and the doctor consulted so that, if necessary, a suitable therapy can be instituted. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it/it/responsabili.

Special warnings

In case of persistence or aggravation of symptoms after drinking treatment period, consult your doctor, in any case, the product should not be used for more than 4 consecutive days. If you have the appearance of side effects in a period of less than 4 days, stop the therapy and consult your doctor. The product is not suitable for the treatment of infections, pus, foreign bodies in the eye, mechanical, chemical and heat damage. Such conditions require the attention of the doctor. Although the product has poor serum absorption, it should be used with caution in patients suffering from hypertension, hyperthyroidism, cardiac disorders, hyperglycemia (Diabetes) and bronchial asthma. Since the product contains Benzalkonium Chloride, soft contact lenses should not be worn during treatment. If contact lenses are used, they must be removed prior to instillation of the eye drops and can be reapplied after 15 minutes.Keep out of reach of children as accidental ingestion can cause CNS depression (marked sedation hypotonia, coma). In these cases it always is immediate medical attention is required.

Pregnancy and breastfeeding

During pregnancy and lactation use only in case of real need, under the direct supervision of the doctor.

Expiration and retention

This medicinal product does not require any special storage conditions. The shelf life after first opening the bottle is 28 days.

Interactions with other drugs

IRIDINA DUE should not be used by subjects being treated with antidepressant drugs (MAOIs) and in the two weeks following such treatment as severe hypertensive crises can occur.


In case of overdose due to accidental oral administration, there may be manifestations of depression in the central nervous system with phenomena of bradypnea, cold sensation in the skin, drowsiness, tachycardia, sweating, mental confusion and coma. If this happens: gastric lavage, sedation with diazepam and general supportive measures.

Active principles

10 ml of eye drops contain: Active ingredient: Naphazoline hydrochloride 5 mg Excipients: Benzalkonium chloride


Sodium chloride, Sodium dihydrogen phosphate dihydrate, Sodium hydroxide, Sodium hyaluronate, Benzalkonium chloride, Hamamelis distilled water, Chamomile distilled water, Purified water


Data sheet

0.5 mg / ml eye drops, solution 10 ml
Product Type
ATC code
ATC description
Therapeutic Group
Active principle
naphazoline hydrochloride (FU)
Pharmaceutical form
eye drops
Type of Administration
1 vial / vial / vial
10 milliliters
Quantity of the Active Ingredient
, 5MG
Recipe required
OTC - self-medication medicine
chat Comments (0)
Fast Order